{"title":"[慢性肾病引起的贫血]。","authors":"L Bukmir, M Fišić, I Diminić-Lisica, A Ljubotina","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>Renal anemia develops secondary to chronic kidney disease (CKD) and its incidence increases with the progression of CKD.\nThe aim is to inform family physicians about the latest developments and ways of approaching the issue, in accordance\nwith national guidelines. The PubMed and Cochrane systematic reviews databases were searched for the 1996-2015 period\nusing the following key words: anemia, chronic renal failure, erythropoietin, and primary health care. In addition, all relevant\narticles and textbooks available were manually searched to suggest the following conclusions. The use of erythropoiesis-stimulating\nagents (ESA) slows down the progression of CKD, reduces the need for blood transfusions and improves the\npatient quality of life. Target hemoglobin (Hb) concentration to be permanently maintained is 110-120 g/L. Higher Hb levels\nare associated with higher mortality and major cardiovascular events in dialysis patients. Target hemoglobin level should\nbe strictly individualized depending on CKD stage (both non-dialyzed and dialyzed population), age, other risks, initial and\nmaintenance treatment. Early recognition and appropriate correction of anemia using ESA is of utmost importance in CKD\npatients. Systematic primary and secondary prevention measures along with education and professional implementation\nof national guidelines in daily work of family practitioners can improve medical care of patients with CKD.</p>","PeriodicalId":35756,"journal":{"name":"Acta Medica Croatica","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2016-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"[ANEMIA IN CHRONIC KIDNEY DISEASE].\",\"authors\":\"L Bukmir, M Fišić, I Diminić-Lisica, A Ljubotina\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Renal anemia develops secondary to chronic kidney disease (CKD) and its incidence increases with the progression of CKD.\\nThe aim is to inform family physicians about the latest developments and ways of approaching the issue, in accordance\\nwith national guidelines. The PubMed and Cochrane systematic reviews databases were searched for the 1996-2015 period\\nusing the following key words: anemia, chronic renal failure, erythropoietin, and primary health care. In addition, all relevant\\narticles and textbooks available were manually searched to suggest the following conclusions. The use of erythropoiesis-stimulating\\nagents (ESA) slows down the progression of CKD, reduces the need for blood transfusions and improves the\\npatient quality of life. Target hemoglobin (Hb) concentration to be permanently maintained is 110-120 g/L. Higher Hb levels\\nare associated with higher mortality and major cardiovascular events in dialysis patients. Target hemoglobin level should\\nbe strictly individualized depending on CKD stage (both non-dialyzed and dialyzed population), age, other risks, initial and\\nmaintenance treatment. Early recognition and appropriate correction of anemia using ESA is of utmost importance in CKD\\npatients. Systematic primary and secondary prevention measures along with education and professional implementation\\nof national guidelines in daily work of family practitioners can improve medical care of patients with CKD.</p>\",\"PeriodicalId\":35756,\"journal\":{\"name\":\"Acta Medica Croatica\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2016-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Acta Medica Croatica\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Medica Croatica","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
Renal anemia develops secondary to chronic kidney disease (CKD) and its incidence increases with the progression of CKD.
The aim is to inform family physicians about the latest developments and ways of approaching the issue, in accordance
with national guidelines. The PubMed and Cochrane systematic reviews databases were searched for the 1996-2015 period
using the following key words: anemia, chronic renal failure, erythropoietin, and primary health care. In addition, all relevant
articles and textbooks available were manually searched to suggest the following conclusions. The use of erythropoiesis-stimulating
agents (ESA) slows down the progression of CKD, reduces the need for blood transfusions and improves the
patient quality of life. Target hemoglobin (Hb) concentration to be permanently maintained is 110-120 g/L. Higher Hb levels
are associated with higher mortality and major cardiovascular events in dialysis patients. Target hemoglobin level should
be strictly individualized depending on CKD stage (both non-dialyzed and dialyzed population), age, other risks, initial and
maintenance treatment. Early recognition and appropriate correction of anemia using ESA is of utmost importance in CKD
patients. Systematic primary and secondary prevention measures along with education and professional implementation
of national guidelines in daily work of family practitioners can improve medical care of patients with CKD.
期刊介绍:
ACTA MEDICA CROATICA publishes original contributions to medical sciences, that have not been previously published. All manuscripts should be written in English.